S. J. Harland - Concepedia

Author

S. J. Harland

Medical Research Council

Also Known As

P Clark, S Harland, S J Harland, S. Harland, S. J. HARLAND, S. J. Harland, S.J. HARLAND, S.J. Harland, SJ Harland

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Medical Research Council North Middlesex Hospital Institute of Cancer Research University College London Royal Marsden Hospital

About

S. J. Harland is an author at Medical Research Council specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	1.2K
2	Biochemistry	4	4	180
3	Engineering	2	2	106
4	Health Sciences	2	2	227
5	Natural Sciences	1	1	29

S. J. Harland

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2 Peter Palmer, J. Vinke, Thierry Philip, Annals of Oncology Prognostic FactorsUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	1992	156
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Smith Ie, S. J. Harland, Bridget A. Robinson, PubMed Cisplatin AnalogCombination ChemotherapyMedicinePharmacologyPathology	1985	147
Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system K. D. Bagshawe, S. J. Harland Cancer ImmunologyPathologyGynecologyCsf Hcg ConcentrationNeuro-oncology	1976	125
Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. S. J. Harland, Pat Cook, S.D. Fosså, PubMed	1998	124
INTRATUBULAR GERM CELL NEOPLASIA OF THE CONTRALATERAL TESTIS IN TESTICULAR CANCER: DEFINING A HIGH RISK GROUP S. J. Harland, Pat Cook, Sophie D. Fosså, The Journal of Urology SpermatogenesisHigh Risk GroupContralateral TestisPathologyCarcinoma	1998	119
Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. B D Evans, K. Srujan Raju, A H Calvert, PubMed Tumoral PathologyMedicineNew Platinum AnalogMetronomic TherapyPathology	1983	114
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. A H Calvert, D Alison, S. J. Harland, Journal of Clinical Oncology PathologyPharmacotherapyPharmaceutical ChemistryPre-clinical PharmacologyDrug Resistance	1986	102
Amplification of the androgen receptor gene in bone metastases from hormone‐refractory prostate cancer Richard S. Brown, Joanne Edwards, Ahmet Doǧan, The Journal of Pathology Androgen ReceptorEndocrine OncologyUrologyHrpc PatientsEngineering	2002	90
Hydralazine, antinuclear antibodies, and the lupus syndrome. R. Mansilla-Tinoco, S. J. Harland, Paul Ryan, BMJ Cumulative DoseAutoimmune DiseaseSystemic Lupus ErythematosusSystemic Lupus Erythematosus TreatmentLupus	1982	81
High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma Ian E. Smith, B D Evans, S. J. Harland, Cancer Chemotherapy and Pharmacology Hematological MalignancyConventional ChemotherapyHigh-dose CyclophosphamideMedicinePathology	1985	75

Page 1